Bijlsma Johannes W J
Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands.
Pol Arch Med Wewn. 2010 Sep;120(9):347-53.
Three important concepts have become standard of care in treating rheumatoid arthritis (RA): 1) development of new drugs: biologic agents; 2) treatment strategies: not an individual drug, but the timely combination of different drugs, given as a specific strategy; 3) treat to target: targeting treatment to the individual patient and adapting treatment when necessary. These concepts led to the development of the European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs. Three so called overarching principles have been formulated, followed by 15 concrete recommendations for the management of RA. These 15 recommendations are described and discussed in this review, with some personal comments. An enormous gain in the development of RA has been achieved, and it is now time to consolidate that gain and make optimal treatment available for every RA patient in Europe. The guidelines described in this article will help physicians to actually do so.
在类风湿关节炎（RA）治疗中，有三个重要概念已成为标准治疗方法：1）新药研发：生物制剂；2）治疗策略：不是单一药物，而是不同药物的适时联合，作为一种特定策略使用；3）达标治疗：针对个体患者进行靶向治疗，并在必要时调整治疗方案。这些概念促成了欧洲抗风湿病联盟关于使用合成和生物改善病情抗风湿药治疗类风湿关节炎（RA）的建议的制定。已制定了三项所谓的总体原则，随后是15条关于RA管理的具体建议。本综述对这15条建议进行了描述和讨论，并给出了一些个人评论。在RA治疗发展方面已取得了巨大进展，现在是巩固这一进展并让欧洲的每一位RA患者都能获得最佳治疗的时候了。本文所述的指南将帮助医生切实做到这一点。
